Atossa Therapeutics Inc. (NASDAQ: ATOS)
$1.40
+0.0900 ( +6.87% ) 1.7M
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
Market Data
Open
$1.40
Previous close
$1.31
Volume
1.7M
Market cap
$176.06M
Day range
$1.28 - $1.42
52 week range
$0.62 - $2.31
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
3 | Insider transactions | 2 | Mar 14, 2024 |
8-k | 8K-related | 13 | Mar 12, 2024 |
4 | Insider transactions | 1 | Nov 17, 2023 |
4 | Insider transactions | 1 | Nov 15, 2023 |
3 | Insider transactions | 2 | Nov 15, 2023 |
4/a | Other | 1 | Nov 15, 2023 |
10-q | Quarterly Reports | 69 | Nov 13, 2023 |
8-k | 8K-related | 14 | Nov 13, 2023 |
8-k | 8K-related | 13 | Nov 09, 2023 |
3 | Insider transactions | 2 | Oct 16, 2023 |